Simulations Plus (SLP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Jul, 2026Executive summary
Shareholders are asked to vote on a merger agreement where the company will be acquired for $18.50 per share in cash, representing a 26% premium to the 60-day average trading price prior to the announcement.
The board unanimously recommends approval of the merger, citing a robust auction process, strategic challenges, and the fairness opinion from Morgan Stanley.
If approved, the company will become a wholly owned subsidiary of the acquirer and will be delisted from Nasdaq.
The merger is expected to close in the second half of 2026, subject to regulatory approvals and shareholder vote.
Voting matters and shareholder proposals
Shareholders will vote on: (1) the merger agreement, (2) an advisory vote on executive compensation related to the merger, and (3) potential adjournment of the meeting to solicit more votes if needed.
Approval of the merger requires a majority of outstanding shares; failure to vote or abstentions count as votes against.
Dissenters' rights are available under California law for shareholders who do not vote in favor.
Board of directors and corporate governance
The board conducted a formal auction process, reviewed multiple bids, and selected the winning offer after negotiations and due diligence.
A voting agreement was secured with major shareholders representing 15.9% of shares, who have agreed to support the merger.
The board considered both positive and negative factors, including strategic alternatives, market conditions, and the certainty of cash consideration.
Latest events from Simulations Plus
- Shareholders to vote on $18.50/share cash merger, with board unanimous support and 26% premium.SLP
Proxy filing - Q3 FY26 revenue up 7%, services up 20%, net income $3.6M, merger at $18.50/share pending.SLP
Q3 2026 - Shareholders to vote on $18.50/share cash merger, with board unanimous support and 26% premium.SLP
Proxy filing - OBESITYsym predicts weight loss and nausea for obesity drugs, validated across diverse populations.SLP
Status update - Q2 2026 revenue up 8% to $24.3M, with higher margins and strong outlook despite EPS guidance cut.SLP
Q2 2026 - Q1 revenue fell 3% to $18.4M as services rose 16%, software dropped 17%, and guidance was reaffirmed.SLP
Q1 2026 - FY25 guidance targets $90M-$93M revenue, 31%-33% EBITDA margin, and expanded market reach.SLP
Stephens 26th Annual Investment Conference | NASH2024 - FY24 revenue up 18% to $70M; FY25 guidance strong with Pro-ficiency driving growth.SLP
Q4 2024 - $100M acquisition doubles market, expands platform, and boosts 2025 EPS outlook.SLP
M&A Announcement